Replies to post #32314 on Cytodyn Inc (CYDY)

[Inoviorulez]

They are bad when done with no catalysts. As I stated if they do one, 1 or 2 days before the BLA filing that's good. For instance, reverse split on a Monday, then the very next day release BLA filing news. That would work. However, a reverse stock split for no reason = bad. Get the drift now?

Example, Sarepta Therapeutics did a reverse stock split 1 to 2 days before releasing its phase 2 DMD results. The stock shot up to 12 the first day, then 24 the very next day.

It's all bout the context. if they time it with a BLA filing or partnership it's good to do a reverse split.

[trding]

My other otc stock announced a possibility of several reverse splits with their uplist. The problem is their intention of selling more shares after the split. A company that needs to sell shares to continuing raising cash should never r/s to uplist in my opinion, because shorts can hit it very hard and wait for the next lot of shares sold in a cash raise to cover. I bet if you look at those examples of a stock running after a R/S and then dropping, the drop was from new shares being sold. What would stink, and I have seen, is the new O/S going back to the pre-R/S levels with shares sold, which means the post R/S price goes back to the pre-R/S price with just a fraction of the shares one had before. So I'm out until after the dust settles. Once the company is self-sustaining with revenue and no longer needs to increase the O/S, then yeah, I could possible support a move. It will not be needed here though if the revenue is anywhere close to the predicted market potential. Look one more time at these old numbers I posted last month: O/S, revenue, and share price at that time for these companies. If leronlimab can make 10B+ a year with mono, combo, and cancer, what should the sp here be with a max 600k O/S?

Gilead
O/S 1,293,619,612
SP $71.18
Market Cap $92,079,843,982
Annual Revenue 26.11 B
P/S Ratio 3.5

Bristol-Myers
O/S 1,632,198,774
SP $53.39
Market Cap $87,143,092,544
Annual Revenue 20.79B
P/S Ratio 4.2


GlaxoSmithKline
O/S 2,686,276,910
SP $41.30
Market Cap $110,943,236,383
Annual Revenue 30B
P/S Ratio 3.7

Johnson & Johnson
O/S 2,681,977,969
SP $145.34
Market Cap $389,798,678,014
Annual Revenue $76.5B
P/S Ratio 5.1

Merck & Co
O/S 2,600,376,500
SP $74.86
Market Cap $194,664,184,790
Annual Revenue $40B
P/S Ratio 4.9

Pfizer
O/S 5,862,109,503
SP $44.28
Market Cap $259,574,208,793
Annual Revenue $52.5B
P/S Ratio 4.9